photo by Moscow City Hall
The construction of the “Generium-Next” began in 2022, and it was commissioned in September 2025
-
The new plant will produce finished dosage forms and handle the secondary packaging of complex genetically engineered drugs for the treatment of orphan and socially significant diseases. The production will include:
- The world's first biosimilars of eculizumab and dornase alfa.
- The first Russian biosimilars of imiglucerase, omalizumab, and alteplase.
«Today, GENERIUM is significantly expanding its production by launching over 28,000 square meters of new facilities. The cutting-edge equipment here will help supply our country's healthcare system with medicines. We will produce up to 5.4 million vials per year in accordance with Russian and international GMP standards. This will ensure uninterrupted patient access to the most advanced therapies,» said Alexander Andryushchechkin, CEO of Generium-Next LLC.
«Eight production facilities are already operating at the special economic zone sites in Zelenograd and Pechatniki. Today, on Moscow Industry Day, we are opening the ninth super-modern plant - 'Generium-Next' - here in Alabushevo,» Sergey Sobyanin noted
Moscow Mayor Sergey Sobyanin attended the grand opening ceremony of the 'Generium-Next' plant.
The plant will create over 250 jobs for the city. The 'Generium-Next' facility was built with financial support from the Industrial Development Fund.
